Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial - Theodore D. Ruel, Edward P. Acosta, Jessica P. Liu, Kathryn P. Gray, Kathleen George, Nicole Montañez, Stephanie Popson, Ann M. Buchanan, Mattie Bartlett, Dale Dayton, Patricia Anthony, Cynthia Brothers, Cynthia Vavro, Rajendra Singh, Lucy Koech - Dissemin

Language
Login

Published in

Elsevier, The Lancet HIV, 5(9), p. e332-e340, 2022

DOI: 10.1016/s2352-3018(22)00044-3

Links

Tools

Export citation

Search in Google Scholar

Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial

Journal article published in 2022 by Theodore D. Ruel, Edward P. Acosta, Jessica P. Liu, Kathryn P. Gray, Kathleen George, Nicole Montañez, Stephanie Popson, Ann M. Buchanan, Mattie Bartlett, Dale Dayton, Patricia Anthony, Cynthia Brothers, Cynthia Vavro, Rajendra Singh, Lucy Koech and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO